Elegen and Nutcracker Therapeutics have partnered to pilot a fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapies. The combined approach addresses limitations of traditional bacterial-derived DNA template production and slow RNA synthesis by enabling rapid, scalable, and contamination-free GMP production. The new platform promises a three-week turnaround from RNA design to drug formulation, significantly accelerating accessibility, cost-efficiency, and scalability of personalized cancer treatments.